Evoked retinal and cortical potentials in children with advanced and resistant retinoblastoma after neoadjuvant polychemotherapy and superselective intra-arterial chemotherapy

Zueva M.V.; Tsapenko I.V.; Saakian S.V.; Panteleeva O.G.; Zharua A.A.; Orlovskaia L.S.

doi:https://doi.org/

Zueva M.V.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdravsotsrazvitiia Rossii

Tsapenko I.V.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdrava Rossii

Saakian S.V.

Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia

Panteleeva O.G.

Dorozhnaia klinicheskaia bol'nitsa na st. Gor'kiĭ OAO RZhD

Zharua A.A.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdrava Rossii

Orlovskaia L.S.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdrava Rossii

Evoked retinal and cortical potentials in children with advanced and resistant retinoblastoma after neoadjuvant polychemotherapy and superselective intra-arterial chemotherapy

Authors:

Zueva M.V., Tsapenko I.V., Saakian S.V., Panteleeva O.G., Zharua A.A., Orlovskaia L.S.

More about the authors

Journal: Russian Annals of Ophthalmology. 2014;130(5): 22‑29

Read: 1042 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zueva MV, Tsapenko IV, Saakian SV, Panteleeva OG, Zharua AA, Orlovskaia LS. Evoked retinal and cortical potentials in children with advanced and resistant retinoblastoma after neoadjuvant polychemotherapy and superselective intra-arterial chemotherapy. Russian Annals of Ophthalmology. 2014;130(5):22‑29. (In Russ.)

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Electrophysiological examinations (in accordance with the ISCEV Standards and original protocols) were performed after neoadjuvant chemotherapy or before and after superselective intra-arterial chemotherapy (SIACT) in 18 children aged 1-3 years with either newly diagnosed advanced retinoblastoma (8 eyes) or resistant retinoblastoma (14 eyes). The most considerable decrease in amplitude was demonstrated by the cone response b-wave, photopic 24 Hz flicker electroretinogram (ERG), photopic negative response, and the P1-component of multifocal ERG, indicating a significant dysfunction of bipolar and ganglion cells, more pronounced in the macular zone. After the SIACT, central retinal functions improved. In eyes with retinoblastoma there is a moderate peak latency shortening of the flash visual evoked potential (VEP) P2-component, which reflects functional changes in the central retina rather than those in the visual pathways, and therefore, flash VEP analysis is a useful tool of chemotherapy patient monitoring, especially when electroretinography cannot be performed.

Keywords:

retinoblastoma

visual evoked cortical potential

electroretinography

superselective intra-arterial chemotherapy.

Authors:

Zueva M.V.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdravsotsrazvitiia Rossii

Tsapenko I.V.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdrava Rossii

Saakian S.V.

Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia

Panteleeva O.G.

Dorozhnaia klinicheskaia bol'nitsa na st. Gor'kiĭ OAO RZhD

Zharua A.A.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdrava Rossii

Orlovskaia L.S.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdrava Rossii

Close metadata

References:

Abramson D.H. Chemosurgery for retinoblastoma: what we know after 5 years. Arch. Ophthalmol. 2011; 129 (11): 1492-1494.
Abramson D.H., Marr B.P., Dunkel I.J., Brodie S., Zabor E.C., Driscoll S.J., Gobin Y.P. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding. Brit. J. Ophthalmol. 2012; 96: 499-502.
Gobin Y.P., Dunkel I.J., Marr B.P., Brodie S.A., Abramson D.H. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch. Ophthalmol. 2011; 129 (6): 732-737.
Suzuki S., Yamane T., Mohri M., Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011; 118 (10): 2081-2087.
Abramson D.H., Dunkel I., Brodie S.E., Marr B.P., Gobin Y.P. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010; 117 (8): 1623-1629.
Gobin Y.P., Dunkel I.J., Marr B.P., Francis J.H., Brodie S.E., Abramson D.H. Combined, Sequential Intravenous and Intra-Arterial Chemotherapy (Bridge Chemotherapy) for Young Infants with Retinoblastoma. PLoS ONE 2012; 7(9): e44322. doi:10.1371/ journal.pone.0044322
Jehanne M., Lumbroso-Le Rouic L., Savignoni A., Aerts I., Mercier G., Bours D., Desjardins L., Doz F. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral orbilateral retinoblastoma. Pediatr. Blood Cancer. 2009; 52 (5): 637-643.
Rizzuti A.E., Dunkel I.J., Abramson D.H. The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch. Ophthalmol. 2008; 126: 862-865.
Shields C.L., Bianciotto C.G., Jabbour P., Ramasubramanian A., Lally S.E., Griffin G.C., Rosenwasser R., Shields J.A. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch. Ophthalmol. 2011; 129 (11): 1407-1415.
Harbour J.W., Murray T.G., Hamasaki D., Cicciarelli N., Hernandez E., Smith B., Windle J., O'Brien J.M. Local carboplatin therapy in transgenic murine retinoblastoma. Invest. Ophthalmol. Vis. Sci. 1996; 37: 1892-1989.
Ripps H., Carr R.E., Siegel I.M., Greenstein V.C. Functional abnormalities in vincristine-induced night blindness. Invest. Ophthalmol. Vis. Sci. 1984; 25: 787-794.
Abramson D.H., Dunkel I., Brodie S.E., Kim J.W., Gobin Y.P. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008; 115 (8): 1398-1404.
Brodie S.E., Gobin Y.P., Dunkel I.J., Kim J.W., Abramson D.H. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc. Ophthalmol. 2009; 119 (1): 13-22.
Brodie S.E., Paulus Y.M., Patel M., Gobin Y.P., Dunkel I.J., Marr B.P., Abramson D.H. ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma. Brit. J. Ophthalmol. 2012; 96 (6): 877-880.
Odom J.V., Bach M., Brigell M., Holder G.E., McCulloch D.L., Tormene A.P., Vaegan. ISCEV standard for clinical visual evoked potentials (2009 update). Doc. Ophthalmol. 2010; 120: 111-119.
Marmor M.F., Fulton A.B., Holder G.E., Miyake Y., Brigell M., Bach M. Standard for clinical electroretinography (2008 update). Doc. Ophthalmol. 2009; 118: 69-77.
Viswanathan S., Frishman L.J., Robson J.G., Harwerth R.S., Smith E.L. The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 1999; 40 (6): 1124-1136.
Rangaswamy N.V., Shirato S., Kaneko M., Digby B.I., Robson J.G., Frishman L.J. Effects of spectral characteristics of Ganzfeld stimuli on the photopic negative response (PhNR) of the ERG. Invest. Ophthalmol. Vis. Sci. 2007; 48: 4818-4828.
Zueva M.V., Neroev V.V., Tsapenko I.V., Sarygina O.I., Ryabina M.V., Grinchenko M.I., Zaitseva S.I. Topographic diagnosis of retinal dysfunctions in rhegmatogenous retinal detachment by rhythmical ERG method wide spectrum of frequencies. Rossiiskii oftal'mologicheskii zhurnal. 2008; (2): 18-22. (In Russ.)
Hood D.C., Bach M., Brigell M., Keating D., Kondo M., Lyons J.S., Marmor M.F., McCulloch D.L., Palmowski-Wolfe A.M. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc. Ophthalmol. 2012; 124: 1-13.
Zueva M.V., Tsapenko I.V. Structural and functional organization of cells Mueller: the role in development and pathology of the retina. In: Shamshinova A.M., ed. Klinicheskaya fiziologiya zreniya. Ocherki [Clinical physiology of vision]. Moscow: Scientific and medical company "MBN" Publ.; 2006: 128-191. (In Russ.)
Kondo M., Sieving P. Primate photopic sine-wave flicker ERG: vector modelling analysis of component origins using glutamate analogs. Invest. Ophthalmol. Vis. Sci. 2001; 42: 305-312.
Zueva M., Tsapenko I., Pak N., Vaskov S. What does the flicker ERG reflect in rabbit retina? In: Abstracts of 42nd ISCEV Symposium. Puerto-Rico; 2004: 54.
Demirci H., Shields C.L., Meadows A.T., Shields J.A. Long-term visual outcome following chemoreduction for retinoblastoma. Arch. Ophthalmol. 2005; 123: 1525-1530.
Desjardins L., Chefchaouni M.C., Lumbroso L., Levy C., Asselain B., Bours D., Dendale R., Estève M., Michon J., Doz F. Functional results after treatment of retinoblastoma. J. AAPOS. 2002; 6: 108-111.
Shields C.L., Honavar S.G., Meadows A.T., Shields J.A., Demirci H., Naduvilath T.J. Chemoreduction for unilateral retinoblastoma. Arch. Ophthalmol. 2002; 120: 1653-1658.
Balasubramanya R., Pushker N., Bajaj M.S., Rani A., Ghose S., Arya L.S. Visual outcome in macular retinoblastoma treated with primary chemotherapy. Ophthalmologica. 2003; 217: 417-421.
Ghose S., Nizamuddin S.H., Sethi A., Mohanti K.B.K., Kumar H., Arya S.L.S., Thavaraj V. Efficacy of induction chemotherapy in retinoblastoma, alone or combined with other adjuvant modalities. J. Pediatr. Ophthalmol. Strasbimus. 2002; 39: 143-150.
Schefler A.C., Cicciarelli N., Feuer W., Toledano S., Murray T.G. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007; 114: 162-169.
Weiss A.H., Kelly J.P., Kapur R.P., Pendergrass T. Retinal function and corresponding pathology in advanced retinoblastoma. Arch. Ophthalmol. 2008; 126: 1507-1512.